• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Savara Inc (NQ: SVRA )

    3.620 -0.080 (-2.16%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 773,466
    Open 3.700
    Bid (Size) 3.280 (1)
    Ask (Size) 3.650 (140)
    Prev. Close 3.700
    Today's Range 3.500 - 3.750
    52wk Range 3.115 - 5.700
    Shares Outstanding 114,066,080
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference
    From Savara Inc.
    Via Business Wire
    Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV
    From Savara Inc.
    Via Business Wire

    Performance

    YTD
    -17.16%
    -17.16%
    1 Month
    -3.21%
    -3.21%
    3 Month
    -13.40%
    -13.40%
    6 Month
    -31.18%
    -31.18%
    1 Year
    -1.09%
    -1.09%

    More News

    Read More
    SVRA Stock Earnings: Savara Misses EPS for Q2 2024
    Via InvestorPlace
    Savara Announces New Employment Inducement Grant
    From Savara Inc.
    Via Business Wire
    Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting
    From Savara Inc.
    Via Business Wire
    Savara Announces New Employment Inducement Grant
    From Savara Inc.
    Via Business Wire
    Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
    From Savara Inc.
    Via Business Wire
    Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
    From Savara Inc.
    Via Business Wire
    Savara to Host Analyst and Investor Webinar on September 30, 2024
    From Savara Inc.
    Via Business Wire
    Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
    From Savara Inc.
    Via Business Wire
    Savara Announces New Employment Inducement Grant
    From Savara Inc.
    Via Business Wire
    Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    From Savara Inc.
    Via Business Wire
    Savara Announces New Employment Inducement Grant
    From Savara Inc.
    Via Business Wire
    Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024
    From Savara Inc.
    Via Business Wire
    Savara Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Savara Inc.
    Via Business Wire
    Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
    From Savara Inc.
    Via Business Wire
    Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday?
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
    From Savara Inc.
    Via Business Wire
    Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
    From Savara Inc.
    Via Business Wire
    3 Penny Stocks Poised for Major Upside Over the Next 5 Years
    Via InvestorPlace
    3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
    Via InvestorPlace
    Savara to Present at the Jefferies Global Healthcare Conference
    From Savara Inc.
    Via Business Wire
    Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
    From Savara Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.